>>Tandem Labs to Offer BioVeris Products for Analytical Services
Wednesday July 19, 8:00 am ET
First CRO to Offer GLP-Compliant Assay Services Using BioVeris' M-SERIES
GAITHERSBURG, Md. and SALT LAKE CITY, July 19 /PRNewswire-FirstCall/ -- BioVeris Corporation (Nasdaq: BIOV - News) and Tandem Laboratories, a leading contract research organization (CRO) providing bioanalytical and immunoanalytical testing to the pharmaceutical industry, announced today that Tandem is the first CRO to offer Good Laboratory Practices (GLP) compliant assay services using BioVeris' products.
Tandem acquired the BioVeris M-SERIES® Analyzer, reagents and BioVerification training to expand their offering of premiere assay technologies for biotechnology and pharmaceutical customers. Tandem already offers traditional ELISA assay services and wanted to add new methods that offered greater sensitivity, dynamic range and drug tolerance for GLP- compliant immunogenicity testing.
Tandem's Vice President and General Manager of the Biomarker and Immunoanalytical Division, Ira DuBey, said, "We chose BioVeris' assay platform to complement our other methodologies for its advantages in assay performance, especially in pharmacokinetic and immunogenicity assays. Today, many more of our clients ask for BioVeris' ECL detection for their assays, and Tandem Laboratories is focused on delivering the highest quality testing coupled with customized service to our clients."
BioVeris' Chief Executive Officer, Samuel Wohlstadter, stated, "We are pleased that Tandem Laboratories is the first CRO to adopt the M-SERIES platform for bioanalytical testing. We welcome Tandem as an experienced and well trained company that can support life science customers."
BioVeris and Tandem believe that immunogenicity testing will become a large percentage of pharmaceutical drug development tests with the increased number of biotech products on the market. A paper issued by pharmaceutical and Food and Drug Administration experts in the Journal of Immunological Methods (volume 289, pages 1-16, 2004) illustrated many of the advantages of BioVeris' ECL technology compared to other methods available for immunogenicity testing.<<
I haven't been paying much attention recently. Since Stuart's post about Roche possibly being caught again, there have been sign of actual marketing activity. What happened to the legal activity that was the chief focus of the company after the IGEN buyout? What's happening in JakeGate, etc.? Anyone know?
Cheers, Tuck |
